| CTRI Number |
CTRI/2026/01/100857 [Registered on: 12/01/2026] Trial Registered Prospectively |
| Last Modified On: |
18/08/2026 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Observational |
|
Type of Study
|
Cross Sectional Study |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
How Medicines Are Used in Chronic Kidney Disease Patients in a Tertiary Care Hospital |
|
Scientific Title of Study
|
A Prospective, Observational study on evaluating Drug Utilization Evaluation and Drug Utilization review on chronic kidney disease patients in a Tertiary Care Hospital. |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Shweta Swaroop |
| Designation |
PG student |
| Affiliation |
Indus International Hospital |
| Address |
Ground floor, Indus International Hospital, Derabassi
Indus International Hospital
Rupnagar
PUNJAB
140507
India |
| Phone |
7876594951 |
| Fax |
|
| Email |
shwetaswa345@gmail.com |
|
Details of Contact Person
Scientific Query
|
| Name |
Dr Parminder Kaur |
| Designation |
Medical Superintendent |
| Affiliation |
Indus International Hospital |
| Address |
Admin block, ground floor, Indus international hospital, Derabassi
Indus International Hospital
Rupnagar
PUNJAB
140507
India |
| Phone |
8872735888 |
| Fax |
|
| Email |
msiih@indushospitals.com |
|
Details of Contact Person
Public Query
|
| Name |
Avantika Chandra |
| Designation |
Manager Clinical Research Department |
| Affiliation |
Indus International Hospital |
| Address |
Department of clinical trial, Admin department, Indus international hospital, Derabassi
Indus International Hospital
Rupnagar
PUNJAB
140507
India |
| Phone |
7991451277 |
| Fax |
|
| Email |
clinicalmanager@indushospitals.com |
|
|
Source of Monetary or Material Support
|
|
|
Primary Sponsor
|
| Name |
Indus International Hospital |
| Address |
Chandigarh-Ambala road Derabassi Punjab 140507 |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Shweta swaroop |
Indus International Hospital |
Admin block, Ground floor, Indus International Hospital
Chandigarh Ambala Highway
Derabassi
SAS Nagar
Punjab
140507
Rupnagar
PUNJAB |
7876594951
shwetaswa345@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Indus International Hospital Institutional Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: N00-N99||Diseases of the genitourinary system, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Nil |
Nil |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
99.00 Year(s) |
| Gender |
Both |
| Details |
Adult patients, CKD patients stage 1-4 |
|
| ExclusionCriteria |
| Details |
patient with acute kidney injury not diagnosed with CKD, patients with incomplete medical record, pediatric patients |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To evaluate drug utilization pattern in CKD patients, To analyze commonly prescribed drug classes such as antihypertensive, diuretics, ESA, phosphate binders and antidiabetics |
baseline, 7 day , 6 month |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| To identify drug related problem in CKD patients, average number of drug per prescription |
baseline , 7 day, 6 month |
|
|
Target Sample Size
|
Total Sample Size="100"
Sample Size from India="100"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
20/01/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="0"
Months="6"
Days="0" |
Recruitment Status of Trial (Global)
Modification(s)
|
Completed |
| Recruitment Status of Trial (India) |
Closed to Recruitment of Participants |
Publication Details
Modification(s)
|
PUBLISHED IN INTERNATIONAL JOURNAL OF SCIENCE RESEARCH TECHNOLOGY. |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
Brief Summary
Modification(s)
|
Chronic Kidney Disease (CKD) is a progressive and irreversible deterioration of kidney function characterized by a decline in glomerular filtration rate (GFR), structural kidney damage, and disturbances in electrolyte, fluid, and acid-base balance. According to the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, CKD is defined as either structural or functional abnormalities of the kidneys persisting for more than three months, with implications for health. It is staged based on the estimated glomerular filtration rate (eGFR) and the degree of proteinuria. Thus, conducting a hospital-based study on DUE and DUR in CKD patients is timely and necessary. It will not only generate baseline data on prescribing practices but also identify gaps in rational prescribing and provide recommendations to improve drug therapy. Ultimately, this study aims to enhance patient safety, therapeutic outcomes, and cost- effectiveness of CKD management |